Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

4D Molecular Therapeutics (FDMT)

4D Molecular Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:FDMT
DateTimeSourceHeadlineSymbolCompany
10/01/202513:36Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FDMT4D Molecular Therapeutics Inc
10/01/202513:00GlobeNewswire Inc.4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash RunwayNASDAQ:FDMT4D Molecular Therapeutics Inc
10/01/202513:00GlobeNewswire Inc.4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational PathNASDAQ:FDMT4D Molecular Therapeutics Inc
16/12/202413:00GlobeNewswire Inc.4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVSNASDAQ:FDMT4D Molecular Therapeutics Inc
11/12/202421:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FDMT4D Molecular Therapeutics Inc
06/12/202421:28Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:FDMT4D Molecular Therapeutics Inc
14/11/202414:13Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:FDMT4D Molecular Therapeutics Inc
14/11/202413:00GlobeNewswire Inc.4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIVNASDAQ:FDMT4D Molecular Therapeutics Inc
13/11/202421:27Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:FDMT4D Molecular Therapeutics Inc
13/11/202421:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FDMT4D Molecular Therapeutics Inc
13/11/202421:05GlobeNewswire Inc.4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming MilestonesNASDAQ:FDMT4D Molecular Therapeutics Inc
08/11/202419:17Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:FDMT4D Molecular Therapeutics Inc
21/10/202420:11Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:FDMT4D Molecular Therapeutics Inc
23/09/202412:00GlobeNewswire Inc.4DMT Announces Presentation at the 2024 North American Cystic Fibrosis ConferenceNASDAQ:FDMT4D Molecular Therapeutics Inc
18/09/202421:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FDMT4D Molecular Therapeutics Inc
18/09/202420:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FDMT4D Molecular Therapeutics Inc
18/09/202420:05GlobeNewswire Inc.4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development DayNASDAQ:FDMT4D Molecular Therapeutics Inc
05/09/202412:00GlobeNewswire Inc.4DMT Announces Presentations at Upcoming Retina ConferencesNASDAQ:FDMT4D Molecular Therapeutics Inc
03/09/202412:00GlobeNewswire Inc.4DMT to Participate in the 2024 Cantor Global Healthcare ConferenceNASDAQ:FDMT4D Molecular Therapeutics Inc
27/08/202412:00GlobeNewswire Inc.4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024NASDAQ:FDMT4D Molecular Therapeutics Inc
21/08/202420:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FDMT4D Molecular Therapeutics Inc
12/08/202412:00GlobeNewswire Inc.4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual ConferenceNASDAQ:FDMT4D Molecular Therapeutics Inc
08/08/202420:14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FDMT4D Molecular Therapeutics Inc
08/08/202420:05GlobeNewswire Inc.4DMT Reports Second Quarter 2024 Financial Results and Operational HighlightsNASDAQ:FDMT4D Molecular Therapeutics Inc
05/08/202412:00GlobeNewswire Inc.4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory BoardNASDAQ:FDMT4D Molecular Therapeutics Inc
23/07/202410:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FDMT4D Molecular Therapeutics Inc
19/07/202400:22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FDMT4D Molecular Therapeutics Inc
17/07/202410:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FDMT4D Molecular Therapeutics Inc
17/07/202409:00GlobeNewswire Inc.4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical ActivityNASDAQ:FDMT4D Molecular Therapeutics Inc
15/07/202422:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FDMT4D Molecular Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:FDMT